In the second quarter of 2026, Precipio posted a 22% revenue increase compared to the same period last year, wrapping up the quarter with more than $3 million in cash and a positive Adjusted EBITDA.
Company achieves all-time high quarterly revenue, returns to positive Adjusted EBITDA, and bolsters cash position
Precipio, Inc. (NASDAQ: PRPO)
NEW HAVEN, CT, UNITED STATES, August 17, 2026 /EINPresswire.com/ — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today disclosed its financial performance for the second quarter ended June 30, 2026.
Precipio, Inc. is a B2i Digital Featured Company. An in-depth company profile is available at: https://b2idigital.com/precipio-inc-1
Key financial metrics for the Company are outlined below. For a full breakdown, please refer to the Company’s Form 10-Q, filed earlier today.
Revenue – $7.0M, compared to $6.7M in Q1-2026 and up 22% year‑over‑year from $5.7M in Q2-2025. This total included $6.1M from pathology services (up from $6.0M in Q1) and $0.9M from product sales (up from $0.66M in Q1).
Adjusted EBITDA – $0.4M, versus $(0.2)M in Q1-2026. The improvement was driven by a $0.3 million revenue increase and a $0.2M reduction in stock‑based compensation expense.
Cash flow – Operating cash flow reached $0.7M in Q2-2026; total cash increased by $0.5 million, yielding a quarter‑end cash balance above $3M, compared to $1.1M in Q2-2025.
“As anticipated, Q2 operating performance reflects a healthy recovery and continued momentum across the business, with customer growth generating quarterly revenue surpassing $7M for the first time in Company history. Product revenues increased 21% from the previous high of $750K in Q4-2025, and cash increased to over $3M.” said Ilan Danieli, CEO of Precipio. “We’ve achieved this level of cash without a financing event, demonstrating the strength of our operations. We’re encouraged by the progress we’ve made and believe we are well positioned to continue building on this momentum.”
A more comprehensive review of the Company’s Q2-2026 performance will be presented during the shareholder call on August 17th, 2026, at 5 PM ET. The call will feature management’s remarks on core business operations, followed by a moderated question‑and‑answer session.
EBITDA and Adjusted EBITDA Reconciliation and Explanation
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non‑GAAP financial measure commonly used to assess operational performance and pre‑tax profitability for emerging growth companies such as ours. Management considers Adjusted EBITDA a useful metric for investors to evaluate the Company’s financial health, especially when non‑cash amortization significantly affects profitability.
Adjusted EBITDA, as defined by us, modifies EBITDA by excluding non‑cash costs related to employee stock options and unusual non‑operating income and expense. The following table reconciles Net Income, EBITDA and Adjusted EBITDA for the second quarters of 2026 and 2025:
EBITDA and Adjusted EBITDA Reconciliation ($ in millions, unaudited)
Net income/(loss) (GAAP): $(0.2) in Q2-2026 vs. $0.1 in Q2-2025
Adjustments to net income/(loss):
Interest expense, net: $0.0 vs. $0.0
Income taxes: $0.0 vs. $0.0
Depreciation: $0.0 vs. $0.1
Amortization of intangibles: $0.2 vs. $0.2
EBITDA (non-GAAP): $0.0 in Q2-2026 vs. $0.4 in Q2-2025
Further adjustments to EBITDA:
Stock-based compensation expense: $0.8 vs. $0.4
Other significant (income) expenses: $(0.4) vs. $(0.9)
Adjusted EBITDA (non-GAAP): $0.4 in Q2-2026 vs. $(0.1) in Q2-2025
About Precipio
Precipio is a healthcare biotechnology company specializing in cancer diagnostics. Its mission is to tackle the widespread problem of cancer misdiagnoses by creating diagnostic products and services that improve accuracy, streamline laboratory workflow, and ultimately enhance patient outcomes while lowering healthcare costs. Within its own laboratory, Precipio develops, tests, validates, and clinically uses these technologies to refine diagnostic results. The Company then markets these innovations as proprietary products serving the global laboratory community, expanding its reach in the fight to eliminate misdiagnosis.
Availability of Other Information About Precipio
For further details, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx), LinkedIn (Precipio), and Facebook. Investors and others should note that the Company communicates with shareholders and the public via its corporate website (https://www.precipiodx.com), which includes—but is not limited to—company disclosures, investor presentations and FAQs, SEC filings, press releases, public conference call transcripts and webcast transcripts, as well as posts on X and LinkedIn. Information shared on the website or social media platforms may be deemed material. Therefore, investors, media, and other interested parties are encouraged to regularly review content posted there. The contents of the website or social media channels are not incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward‑looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this release that are not historical facts should be considered forward‑looking statements, including, without limitation, statements regarding the targets set forth herein and related timing.
Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward‑looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward‑looking statements. These forward‑looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward‑looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward‑looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward‑looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward‑looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523
Media Contact:
David Shapiro
B2i Digital, Inc.
+1 212-579-4844
david@b2idigital.com
Visit us on social media:
LinkedIn
<a href="https://bsky.app/profile/b2id
